Choosing between isatuximab & daratumumab in multiple myeloma

Rahul Banerjee, MD, Fred Hutchinson Cancer Center, Seattle, WA, comments on choosing between isatuximab and daratumumab for the treatment of patients with multiple myeloma in both the frontline and relapsed/refractory (R/R) setting, discussing routes of administration, cost, and clinical trial data. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.